Literature DB >> 6743445

Pharmacokinetics of single-dose i.v. morphine in normal volunteers and patients with end-stage renal failure.

A R Aitkenhead, M Vater, K Achola, C M Cooper, G Smith.   

Abstract

Morphine 0.125 mg kg-1 was administered i.v. to 11 normal subjects and nine patients with chronic renal failure requiring regular haemodialysis. Plasma morphine concentrations were measured using high pressure liquid chromatography (HPLC). Although there was considerable individual variation in both groups, mean plasma concentrations of morphine were significantly higher in the patients with renal failure for 15 min after administration. The decay of plasma concentration fitted a three-compartment mamillary pharmacokinetic model in all subjects. Derived values (mean +/- SEM) of T 1/2 alpha, volume of distribution of the second compartment (V2), total volume of distribution at steady state (Vss) and transfer rate constant from the first to the second compartment (k12), were significantly different between groups. Mean values of terminal elimination half-life (T 1/2 gamma) and total body clearance were similar in the two groups. It was concluded that elimination of unchanged morphine is not impaired significantly in patients with chronic renal failure, although accumulation of morphine-3-glucuronide probably occurs. Although the pharmacological effect of morphine is not related temporally to plasma morphine concentrations, the higher values in patients with renal failure may be implicated in their increased sensitivity to the drug.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6743445     DOI: 10.1093/bja/56.8.813

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  21 in total

Review 1.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

2.  Comparison of the effect of cisapride and metoclopramide on morphine-induced delay in gastric emptying.

Authors:  D J Rowbotham; P A Bamber; W S Nimmo
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

3.  Profound reduction in morphine clearance and liver blood flow in shock.

Authors:  M S Macnab; D J Macrae; E Guy; I S Grant; J Feely
Journal:  Intensive Care Med       Date:  1986       Impact factor: 17.440

Review 4.  Pharmacokinetics of opioids in renal dysfunction.

Authors:  G Davies; C Kingswood; M Street
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

5.  Morphine toxicity with dilated pupils.

Authors:  M P Shelly; G R Park
Journal:  Br Med J (Clin Res Ed)       Date:  1984-10-20

6.  Morphine and morphine-6-glucuronide in the plasma and cerebrospinal fluid of children.

Authors:  R D Hain; A Hardcastle; C R Pinkerton; G W Aherne
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

Review 7.  [Opioids during anesthesia in liver and renal failure].

Authors:  C Höhne; B Donaubauer; U Kaisers
Journal:  Anaesthesist       Date:  2004-03       Impact factor: 1.041

Review 8.  Pharmacological management of cancer pain.

Authors:  S A Schug; R Dunlop; D Zech
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

Review 9.  High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.

Authors:  J Säwe
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

Review 10.  Patient-controlled analgesia. Pharmacokinetic and therapeutic considerations.

Authors:  H F Hill; L E Mather
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.